Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 9, 2015, Pages 1115-1124

  Suen, S C ^a   Bendavid, E ^b,c   Goldhaber Fiebert, J D ^c  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

PPM; Simulation; Xpert MTB RIF

Indexed keywords

RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; INCIDENCE; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MICROSCOPY; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOSIS RAPID TEST; DIAGNOSTIC TEST; ECONOMICS; GENETICS; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NEWBORN; PRESCHOOL CHILD; SPUTUM; THEORETICAL MODEL; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; INDIA; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; QUALITY-ADJUSTED LIFE YEARS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84939147270     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0158     Document Type: Article

References (35)

1. Vandan N, Ali M, Prasad R, Kuroiwa C. Assessment of doctors' knowledge regarding tuberculosis management in Lucknow, India: A public-private sector comparison. Public Health 2009; 123: 484-489.
2. Satyanarayana S, Nair S A, Chadha S S, et al. From where are tuberculosis patients accessing treatment in India? Results from a cross-sectional community based survey of 30 districts. PLOS ONE 2011; 6: E24160.
3. Dye C. The potential impact of new diagnostic tests on tuberculosis epidemics. Indian J Med Res 2012; 135: 737-744.
4. World Health Organization. Cost and cost-effectiveness of public-private mix DOTS: Evidence from two pilot projects in India. WHO/HTM/TB/2004.337. Geneva, Switzerland: WHO, 2004. http://apps.who.int/iris/bitstream/10665/68620/1/WHO-HTM-TB-2004.337.pdf?ua=1 Accessed June 2015.
5. Dewan P K, Lal S S, Lönnroth K, et al. Improving tuberculosis control through public-private collaboration in India: literature review. BMJ 2006; 332: 574-578.
6. Pantoja A, Lönnroth K, Lal S S, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness. Int J Tuberc Lung Dis 2009; 13: 705-712.
7. Acuna-Villaorduna C, Vassall A, Henostroza G, et al. Costeffectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middleincome countries. Clin Infect Dis 2008; 47: 487-495.
8. Pantoja A, Floyd K, Unnikrishnan K P, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis 2009; 13: 698-704.
9. Suen S, Bendavid E, Goldhaber-Fiebert J D. Disease control implications of India's changing multi-drug resistant tuberculosis epidemic. PLOS ONE 2014; 9: E89822.
10. Santha T, Garg R, Frieden T R, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur district, south India, 2000. Int J Tuberc Lung Dis 2002; 6: 780-788.
11. Revised National Tuberculosis Control Programme (RNTCP). Training module for medical practitioners. New Delhi, India: Ministry of Health and Family Welfare, 2010.
12. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. RNTCP performance report, India: Third quarter, 2010. New Delhi, India: Ministry of Health and Family Welfare, 2010. http://www.tbcindia.org Accessed June 2015.
13. Srikanth P, Kamesh S, Daley P. Bleach optimization of sputum smear microscopy for pulmonary tuberculosis. Indian J Tuberc 2009; 56: 174-184.
14. Singla R, Sarin R, Khalid U K, et al. Seven-year DOTS-Plus pilot experience in India: Results, constraints and issues. Int J Tuberc Lung Dis 2009; 13: 976-981.
15. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: A meta-analysis. J Infect 2012; 64: 580-588.
16. Cohesive India. Collaborations for Health System Improvement and Impact Evaluation in India. Durham, NC, USA: Duke University, 2010. http://www.cohesiveindia.org/research-projects.html#best Accessed June 2015.
17. Babiarz K S, Suen S, Goldhaber-Fiebert J D. Tuberculosis treatment discontinuation and symptom persistence: An observational study of Bihar, India's public care system covering < 100, 000, 000 inhabitants. BMC Public Health 2014; 14: 1-13.
18. Cohesive India. Collaborations for Health System Improvement and Impact Evaluation in India. Durham, NC, USA: Duke University, 2010. http://www.cohesiveindia.org/research-projects.html#best Accessed June 2015.
19. Sharma S K, Kumar S, Saha P K, et al. Prevalence of multidrugresistant tuberculosis among Category II pulmonary tuberculosis patients. Indian J Med Res 2011; 133: 312-315.
20. Sachdeva K S. Overview of drug resistant TB in India and national scale up of MDR-TB diagnosis and treatment TB burden in India. Facing the reality of multidrug-resistant tuberculosis: challenges and potential solutions in india, April 18-19. New Delhi, India: Indian National Science Academy, 2011.
21. Gold M R, Siegel J E, Russell L B, Weinstein M C. Costeffectiveness in health and medicine. Oxford, UK: Oxford University Press, 1996.
22. Winetsky D E, Negoescu DM, DeMarchis E H, et al. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: A cost-effectiveness analysis. PLOS MED 2012; 9: E1001348.
23. Salomon J A, Vos T, Hogan D R, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2010; 380: 2129-2143.
24. Dhingra V, Rajpal S. Health related quality of life (HRQL) scoring in tuberculosis. Indian J Tuberc 2003; 50: 99-104. http://medind.nic.in/ibr/t03/i2/ibrt03i2p99.pdf Accessed June 2015.
25. Vassall A, van Kampen, S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: A cost-effectiveness analysis. PLOS MED 2011; 8: E1001120.
26. Stop TB Partnership. Global drug facility product catalogue. Geneva, Switzerland: World Health Organization, 2013.
27. Global Drug Facility, Stop TB Partnership. Buying quality, affordable tuberculosis drugs through the Global Drug Facility: A guide to the Direct Procurement Service for donors, nongovernmental organizations and programme managers. Geneva, Switzerland: World Health Organization, 2013: P 15.
28. World Health Organization. Cost-effectiveness and strategic planning (WHO-CHOICE) tables of costs and prices used in WHO-CHOICE analysis. Geneva, Switzerland: WHO, 2014. http://www.who.int/choice/costs/en/Accessed June 2015.
29. Ferroussier O, Kumar MK A, Dewan P K, et al. Cost and costeffectiveness of a public-private mix project in Kannur District, Kerala, India, 2001-2002. Int J Tuberc Lung Dis 2007; 11: 755-761.
30. Indian Ministry of Statistics and Programme Implementation. NSS Survey Reports. New Delhi, India: Indian Ministry of Statistics, 2014. http://mospi.nic.in/Mospi-New/site/inner.aspx?status=3&menu-id=31 Accessed June 2015.
31. Resch S C, Salomon J A, Murray M, Weinstein M C. Cost effectiveness of treating multidrug-resistant tuberculosis. PLOS MED 2006; 3: E241.
32. Goldhaber-Fiebert J D, Suen S, Babiarz K. Estimating individual medical expenditures from household surveys in the context of urbanization and economic development: India, 1995-2010. Miami, FL, USA: Society for Medical Decision Making, 2014.
33. World Health Organization. Cost-effectiveness and strategic planning (WHO-CHOICE): cost-effectiveness thresholds. Geneva, Switzerland: WHO, 2014. http://www.who.int/choice/costs/CER-thresholds/en/Accessed June 2015.
34. Salje H, Andrews J R, Deo S, et al. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: A transmission model. PLOS MED 2014; 11: E1001674.
35. The World Bank. GDP per capita 2014. Washington DC, USA: The World Bank, 2014: Pp 1-12. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD Accessed June 2015.